Friday, June 19, 2026
🇺🇸 FDA

pharma · COVID-19 · Cystic Fibrosis · ARCT

Arcturus Therapeutics

Arcturus Therapeutics Holdings

Arcturus Therapeutics patent portfolio — 55 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
10285 Science Center Dr, San Diego, California 92121, US HQ
2013 Founded
157 Employees
Public company Type
ARCT · NYSE Ticker
Company details
Status
Public
HQ
10285 Science Center Dr, San Diego, California 92121, US
Founded
2013
Employees
157
Programs
13
Drugs
7
Patents
55
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Arcturus Therapeutics patents

55 pharmaceutical patents indexed for Arcturus Therapeutics. 0 expire within 24 months.

Arcturus Therapeutics has 55 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

55 patents

Patent portfolio

Page 1 of 2

  1. US 12398379

    Compositions and methods for treating ornithine transcarbamylase deficiency

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12390524

    Compositions and methods for inducing immune responses

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12351834

    Compositions and methods for the treatment of ornithine transcarbamylase deficiency

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12290567

    Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12286395

    Method of synthesis of an ionizable cationic lipid

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12220485

    Method of making lipid-encapsulated RNA nanoparticles

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12220455

    Coronavirus vaccine compositions and methods

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12178921

    Method of lyophilizing lipid nanoparticles

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12083224

    Lipid particles for nucleic acid delivery

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12077754

    Synthetic transfer RNA with extended anticodon loop

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12070509

    Nucleic acids and methods of treatment for cystic fibrosis

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11939363

    Translatable molecules and synthesis thereof

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11938227

    Lipid nanoparticles encapsulation of large RNA

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11939600

    Compositions and methods for treating phenylketonuria

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11759515

    Compositions and methods for inducing immune responses

    Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11744887

    Coronavirus vaccine compositions and methods

    Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11737979

    Method of making lipid-encapsulated RNA nanoparticles

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11685921

    Molecules and agents for treating hepatitis B virus

    Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11685906

    Compositions and methods for treating ornithine transcarbamylase deficiency

    Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11434485

    Synthetic transfer RNA with extended anticodon loop

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11407800

    Translatable molecules and synthesis thereof

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11015204

    Synthesis and structure of high potency RNA therapeutics

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10980895

    Ionizable cationic lipid for RNA delivery

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10968248

    Trinucleotide mRNA cap analogs

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10961535

    Compositions and agents against hepatitis B virus and uses thereof

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10815463

    Messenger UNA molecules and uses thereof

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10781169

    Method of synthesis of an ionizable cationic lipid

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10731154

    Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10683500

    UNA oligomers having reduced off-target effects in gene silencing

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10604758

    Therapeutic oligomers for treating amyloidosis

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10556861

    Ionizable cationic lipid for RNA delivery

    Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10519447

    Therapeutic UNA oligomers and uses thereof

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10487105

    Trinucleotide MRNA cap analogs

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10457945

    UNA oligomers for therapeutics with prolonged stability

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10421964

    UNA oligomers and compositions for treating amyloidosis

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10399937

    Ionizable cationic lipid for RNA delivery

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10383952

    Ionizable cationic lipid for RNA delivery

    Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10369232

    Allele selective gene editing and uses thereof

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10227302

    Ionizable cationic lipid for RNA delivery

    Expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9982259

    Transthyretin allele selective UNA oligomers for gene silencing

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9962449

    MultiLigand agent for drug delivery

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9951002

    Ionizable cationic lipid for RNA delivery

    Expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9944929

    UNA single stranded oligomers for therapeutics

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9896413

    Ionizable cationic lipid for RNA delivery

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9856475

    Formulations for treating amyloidosis

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9850202

    Ionizable cationic lipid for RNA delivery

    Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9670152

    Ionizable cationic lipid for RNA delivery

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9593077

    Ionizable cationic lipid for RNA delivery

    Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Arcturus Therapeutics have?

55 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Arcturus Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.